Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surveillance of Using Novel free Radical scavenger, edaravone to Investigate Survival Effect for ALS patients in Japan

Next Previous
X
Search
Trial Profile

Surveillance of Using Novel free Radical scavenger, edaravone to Investigate Survival Effect for ALS patients in Japan

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms SUNRISE
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 01 Dec 2021 According to a Mitsubishi Tanabe Pharma America media release, data from this trial will be presented as part of the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND by Kenta Yoshimura in Dec 2021.
    • 03 Dec 2020 According to a Mitsubishi Tanabe Pharma America media release, data from this trial will be presented as part of the Motor Neurone Disease Association (MNDA) 31st International Symposium on ALS/MND.
    • 18 Apr 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top